- Trials with a EudraCT protocol (288)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
288 result(s) found for: SARS coronavirus.
Displaying page 5 of 15.
EudraCT Number: 2021-000281-15 | Sponsor Protocol Number: mRNA-1273-P204 | Start Date*: 2023-09-19 |
Sponsor Name:ModernaTX, Inc. | ||
Full Title: A Phase 2/3, Three-Part, Open-Label, Dose-Escalation, Age De-escalation and Randomized, Observer-Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and ... | ||
Medical condition: Coronavirus Disease 2019 | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2020-002728-35 | Sponsor Protocol Number: HUN-AVI-01 | Start Date*: 2020-09-17 | |||||||||||
Sponsor Name:Hungarian Ministry of Innovation and Technology - Representative: Hecrin Consortium | |||||||||||||
Full Title: An Investigation of the Efficacy and Safety of Favipiravir in COVID-19 Patients with Mild Pneumonia − An open-label randomized controlled study − | |||||||||||||
Medical condition: Patients with new type of coronavirus (SARS-CoV-2) infection proven by RT-PCR test with mild pneumonia. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-001307-16 | Sponsor Protocol Number: SIC | Start Date*: 2020-04-01 |
Sponsor Name:Fundación para la Investigación Biomédica Hospital Ramón y Cajal | ||
Full Title: Efficacy and Safety of corticoids in patients with adult respiratory distress syndrome (ARDS) secondary to COVID-19. | ||
Medical condition: Adult respiratory distress syndrome (ARDS) secondary to SARS-CoV-2 | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2020-000919-69 | Sponsor Protocol Number: 73249 | Start Date*: 2020-03-17 | |||||||||||
Sponsor Name:University Medical Center | |||||||||||||
Full Title: Reducing health care workers absenteeism in SARS-CoV-2 pandemic by enhanced trained immune responses through Bacillus Calmette-Guérin vaccination, a randomized controlled trial (COVID-19). | |||||||||||||
Medical condition: SARS-CoV-2 infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-005598-28 | Sponsor Protocol Number: ADG20PREV001 | Start Date*: 2021-09-17 | |||||||||||
Sponsor Name:Adagio Therapeutics Inc | |||||||||||||
Full Title: A Phase 2/3 Randomized, Double-blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of ADG20 in the Prevention of COVID-19 (EVADE) | |||||||||||||
Medical condition: The prevention of symptomatic coronavirus (CoV) disease 2019 (COVID 19) in adults and adolescents | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) PL (Prematurely Ended) CZ (Completed) BG (Completed) RO (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-005366-34 | Sponsor Protocol Number: WV43042 | Start Date*: 2021-02-12 | |||||||||||
Sponsor Name:F. Hoffmann La Roche Ltd. | |||||||||||||
Full Title: A PHASE II RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE ANTIVIRAL ACTIVITY, SAFETY, PHARMACOKINETICS, AND EFFICACY OF RO7496998 (AT-527) IN NON-HOSPITALIZED ADULT PATIENTS WI... | |||||||||||||
Medical condition: Coronavirus disease 2019 (COVID-19) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IE (Completed) BG (Completed) ES (Completed) LV (Completed) GR (Completed) LT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-001345-38 | Sponsor Protocol Number: UNIKINON-01/HOPE | Start Date*: 2020-04-02 | |||||||||||
Sponsor Name:Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A. | |||||||||||||
Full Title: CHROLOQUINE PHOSPHATE AGAINST INFECTION BY THE NOVEL CORONAVIRUS SARS-CoV-2 (COVID-19): THE HOPE OPEN-LABEL, NON-RANDOMIZED CLINICAL TRIAL | |||||||||||||
Medical condition: Possible prevention of pneumonia from SARS-CoV-2 in patients staying home and improving symptoms of SARS-CoV-2 pneumonia in patients treated in hospital | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2024-000165-25 | Sponsor Protocol Number: mRNA-1273-P306 | Start Date*: 2024-05-30 |
Sponsor Name:ModernaTX, Inc. | ||
Full Title: An Open-Label, Phase 3 Study to Evaluate the Safety and Immunogenicity of mRNA Vaccines for SARS-CoV-2 Variants in Participants Aged 6 Months to <6 Years | ||
Medical condition: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: (No results available) |
EudraCT Number: 2020-001934-37 | Sponsor Protocol Number: GLUCOCOVID | Start Date*: 2020-05-07 | |||||||||||
Sponsor Name:IDIVAL Instituto de Investigación Sanitaria Valdecilla | |||||||||||||
Full Title: USE OF CORTICOSTEROIDS IN PATIENTS WITH SARS-COV2 CORONAVIRUS INFECTION (GLUCOCOVID). Pragmatic trial inserted in real practice during a pandemic COVID-19 | |||||||||||||
Medical condition: SARS-CoV-2 infection (COVID-19) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-000035-23 | Sponsor Protocol Number: VLA2001-307 | Start Date*: 2022-04-11 | |||||||||||
Sponsor Name:Valneva Austria GmbH | |||||||||||||
Full Title: OPEN-LABEL PHASE 2/3 CLINICAL STUDY TO INVESTIGATE SAFETY AND IMMUNOGENICITY OF A SINGLE VLA2001 BOOSTER VACCINATION IN ADULT VOLUNTEERS, AFTER RECEIPT OF NATIONALLY ROLLED OUT MRNA COVID-19 VACCI... | |||||||||||||
Medical condition: Coronavirus disease (COVID-19) is an infectious disease caused by a newly discovered coronavirus. Most people infected with the COVID-19 virus will experience mild to moderate respiratory illness a... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-001544-26 | Sponsor Protocol Number: RASCOVID-19 | Start Date*: 2020-04-22 | ||||||||||||||||
Sponsor Name:Center for Clinical Metabolic Research, Gentofte Hospital | ||||||||||||||||||
Full Title: Effects of discontinuing renin-angiotensin system inhibitors in patients with and without COVID-19 | ||||||||||||||||||
Medical condition: Coronavirus disease 2019 (COVID-19) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DK (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-001370-30 | Sponsor Protocol Number: CACZ885D2310 | Start Date*: 2020-04-29 | |||||||||||
Sponsor Name:Novartis Pharma AG | |||||||||||||
Full Title: Phase 3 multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of canakinumab on cytokine release syndrome in patients with COVID-19-induced pneumonia (CA... | |||||||||||||
Medical condition: COVID-19-induced pneumonia (CAN-COVID) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA) FR (Completed) ES (Completed) HU (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-001376-15 | Sponsor Protocol Number: VPM1002-DE-3.06CoV | Start Date*: 2020-05-13 | |||||||||||
Sponsor Name:Vakzine Projekt Management GmbH | |||||||||||||
Full Title: A phase III, double-blind, randomized, placebo-controlled multicentre clinical trial to assess the efficacy and safety of VPM1002 in reducing healthcare professionals’ absenteeism in the SARS-CoV-2... | |||||||||||||
Medical condition: infectious respiratory diseases (e.g. COVID-19) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2023-000482-14 | Sponsor Protocol Number: mRNA-1273-P206 | Start Date*: 2024-04-19 |
Sponsor Name:ModernaTX, Inc. | ||
Full Title: A Phase 2, Two-Part Study (Open-Label [Part 1] Followed by Observer-Blind/Randomized [Part 2]) to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA-1273.214 SARS-CoV-2 Va... | ||
Medical condition: Coronavirus Disease 2019 | ||
Disease: | ||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2020-005299-36 | Sponsor Protocol Number: EXEVIR0101 | Start Date*: 2021-04-21 | |||||||||||
Sponsor Name:ExeVir Bio BV | |||||||||||||
Full Title: A 2-part Clinical Study Including a First-in-Human, Open-label, Single Ascending Dose Part (Phase 1) Followed by a Randomised, Double-blind, Placebo-controlled Part (Phase 2) to Evaluate the Effica... | |||||||||||||
Medical condition: Subjects hospitalised for COVID 19 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Prematurely Ended) PT (Prematurely Ended) IT (Prematurely Ended) RO (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-001704-42 | Sponsor Protocol Number: SANsinCOVID | Start Date*: 2020-05-15 | |||||||||||
Sponsor Name:IDIVAL Instituto de Investigación Sanitaria Valdecilla | |||||||||||||
Full Title: Controlled and randomised trial to assess the safety and efficacy of hydroxychloroquine chemoprophylaxis in SARS CoV2 infection in hospital healthcare personnel (Sanitarios sin COVID-19 -SANsinCOVI... | |||||||||||||
Medical condition: SARS-CoV-2 infection (COVID-19) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-005015-40 | Sponsor Protocol Number: IVER-303 | Start Date*: 2021-04-29 | |||||||||||
Sponsor Name:Chemo Research S.L. | |||||||||||||
Full Title: A multicentre, phase III, double-blind, randomised, parallel, placebo-controlled trial to assess efficacy and safety of early administration of Ivermectin during 3 consecutive days to prevent SARS ... | |||||||||||||
Medical condition: Coronavirus disease (COVID-19) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SK (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-006172-16 | Sponsor Protocol Number: CoVVacBoost | Start Date*: 2021-11-26 | |||||||||||
Sponsor Name:Medical University of Graz | |||||||||||||
Full Title: Detection and Characterization of Anti-SARS-CoV-2 Salivary Antibodies after COVID-19 Booster Vaccines – The CoVVacBoost Study | |||||||||||||
Medical condition: Covid (Coronavirus disease)- 19 immunisation | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-001031-27 | Sponsor Protocol Number: CQ4COV19 | Start Date*: 2020-03-14 | ||||||||||||||||
Sponsor Name:FUNDACIÓN FLS DE LUCHA CONTRA EL SIDA, LAS ENFERMEDADES INFECCIOSAS Y LA PROMOCIÓN DE LA SALUD Y LA CIENCIA | ||||||||||||||||||
Full Title: Treatment of non-severe confirmed cases of COVID-19 and chemoprophylaxis of their contacts as prevention strategy: a Cluster Randomized Clinical Trial (PEP CoV-2 Study) | ||||||||||||||||||
Medical condition: SARS-CoV-2 Respiratory Viral Infection | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: ES (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-002503-19 | Sponsor Protocol Number: 62586 | Start Date*: 2020-07-08 | |||||||||||
Sponsor Name:UMC Utrecht | |||||||||||||
Full Title: BCG vaccination to Reduce the impact of COVID-19 in healthcare workers (BRACE) Trial | |||||||||||||
Medical condition: SARS-CoV-2 infection | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
